Anti-Human GITRL

Product No.: G620

[product_table name="All Top" skus="G620"]

- -
- -
Target
GITRL
Product Type
Polyclonal Antibody
Alternate Names
AITRL
Applications
IHC FFPE
,
WB

- -
- -
Select Product Size

Data

G620 Western Blot
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Rabbit
Product Concentration
0.2 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Rabbit Anti-Human GITRL recognizes Human and Mouse GITRL. This polyclonal antibody was purified using affinity chromatography.
Background
The tumor necrosis factor (TNF) and TNF receptor (TNFR) gene superfamilies regulate numerous biological functions including cell proliferation, differentiation, and survival through regulating the activation of the transcription factor NF-κB and various mitogen-activated protein kinases (reviewed in 1). The glucocorticoid-induced tumor necrosis factor receptor (GITR) is an emerging member of this family that is expressed on CD4+ CD25+ regulatory T cells and appears to have crucial immune regulation functions.2,3 Its ligand GITRL is expressed in endothelial and antigen-presenting cells4 and can activate NF-κB, induce both pro- and anti-apoptotic effects, inhibit the suppressive activity of regulatory T cells, and co-stimulate responder T cells through GITR.5 Dominant negative forms of NIK and TRAF2 expressed in transfected 293 cells substantially inhibited NF-κB activation, suggesting that the GITRL-GITR pathway involves both NIK and TRAF2.4
PubMed

References & Citations

1. Gaur, U. et al. (2003) Biochem. Pharmacol. 66:1403
2. Ronchetti, S. et al (2002) Blood 100:350
3. Shimizu, J. et al. (2002) Nat. Immunol. 3:135
4. Gurney, AL. et al. (1999) Curr. Biol. 9:215
IHC FFPE
General Western Blot Protocol

Certificate of Analysis

- -
- -
Prod No.
Description
G620
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.